-
-
-
-
-
-
-
Pacific Bio (PACB) Misses Q2 EPS by 1c
-
-
-
-
-
-
-
Increasing unusual call option volume: FORM PACB CAR DRAM SDGR BFB CYPH MOD SPIR
-
-
-
-
-
-
-
PacBio announces collaboration plans for rare disease therapies
-
-
-
-
-
-
-
PACB announces cost reductions for genome sequencing platforms
-
-
-
-
-
-
-
Bernstein on US Life Science Tools & Diagnostics: 'Why We're More Bullish...'
-
-
-
-
-
-
-
Pacific Bio (PACB) Reports Prelim Q1 Revenue, Affirms FY25 Guidance
-
-
-
-
-
-
-
Increasing unusual call option volume: GT XLI HLF ALGM FROG PACB ABSI
-
479,047 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


